Sinovac Biotech (SVA)
Sinovac Biotech Revenue Growth: 131.3%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SVA Revenue Growth Rankings
| Overall | 97th percentile | 100 of 4363 |
| Sector | 92nd percentile | 32 of 457 in Healthcare |
| Industry | 80th percentile | 25 of 126 in Biotechnology |
SVA Revenue Growth Range, Past 5 Years
| Minimum | -74.88% | Dec 2010 |
| Maximum | 193.5% | Dec 2009 |
| Average | 27.56% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these SVA related companies
SVA News
Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
May 08, 8:00AM PR Newswire
May 08, 8:00AM PR Newswire
Sinovac Participates in Goldman Sachs/Gao Hua Healthcare Corporate Day in Hong Kong
Apr 12, 8:00AM PR Newswire
Apr 12, 8:00AM PR Newswire
Sinovac Biotech (SVA) Independent Director Chup Hung Mok Resigns, New Appointee Named
Mar 29, 6:49AM Street Insider
Mar 29, 6:49AM Street Insider
Sinovac Reports Unaudited Fourth Quarter and Preliminary Full Year 2011 Financial Results
Mar 29, 6:30AM PR Newswire
Mar 29, 6:30AM PR Newswire
Sinovac to Host Conference Call to Report Fourth Quarter 2011 Unaudited Financial Results
Mar 21, 8:00AM PR Newswire
Mar 21, 8:00AM PR Newswire
$nvax $sva $apt $bcrx .. Swine Flu deaths rising http://stks.co/2VAd
about 100 days ago by Sal22Mazzo
about 100 days ago by Sal22Mazzo
$NVAX $BCRX $SVA $APT ... once this news hits mainstream media outlets things can get rolling.. http://stks.co/2VAb
about 100 days ago by Sal22Mazzo
about 100 days ago by Sal22Mazzo
$nvax $bcrx $apt $sva http://stks.co/2Ewc .2009 had 1300 cases up to April.. 2012 has already surpassed that and its only Feb.
about 119 days ago by Sal22Mazzo
about 119 days ago by Sal22Mazzo
32 Die in Mexico from Swine Flu outbreak $NVAX $bcrx $sva $apt http://stks.co/28oQ
about 124 days ago by Sal22Mazzo
about 124 days ago by Sal22Mazzo
$BCRX $SVA $APT $NVAX .. get in b4 its gone... on sale for a limited time only...not an info mercial ..this is the real deal
about 128 days ago by Sal22Mazzo
about 128 days ago by Sal22Mazzo
Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee Requirement
Jan 24, 4:05PM Benzinga
Jan 24, 4:05PM Benzinga
$BCRX $SVA $APT $NVAX ... Bird FLU is creeping into the mainstream news
about 130 days ago by Sal22Mazzo
about 130 days ago by Sal22Mazzo
Flu stocks continue to move higher! Mentioned here several times recently! $NVAX $APT $SVA $BCRX All ready to breakoiut?
about 144 days ago by AceStocks
about 144 days ago by AceStocks
Flu stocks up higher again today! Set up in place for explosive move to upside? $APT $NVAX $SVA http://chart.ly/8irtq92
about 147 days ago by AceStocks
about 147 days ago by AceStocks
Bird flu death in Hong Kong! Flu in USA on the rise! Nevada and KY with high flu activity! $APT up 16% Also $SVA $NVAX
about 150 days ago by AceStocks
about 150 days ago by AceStocks
$NVAX $BCRX $SVA ..Bird Flu in focus...healthaim.com/avian-flu-more-contagious-than-before/
about 150 days ago by Sal22Mazzo
about 150 days ago by Sal22Mazzo
Flu Stocks ready to pop? Bird Flu found in NE Seals on Dec.21! $APT $BCRX $NVAX $SVA Flu Trends rise in US! http://stks.co/1ftA
about 161 days ago by AceStocks
about 161 days ago by AceStocks
Sinovac Biotech, Ltd (SVA) Reports Wider Q3 Loss of $0.04, Revs Stronger
Nov 14, 7:21AM Street Insider
Nov 14, 7:21AM Street Insider
Sinovac to Host Conference Call to Report Third Quarter 2011 Unaudited Financial Results
Nov 07, 8:00AM PR Newswire
Nov 07, 8:00AM PR Newswire
$SVA http://stks.co/mqy Maybe, Just Maybe SVA is Replicating it's Traditional Bottoming Process
HA
about 220 days ago by Bronze
about 220 days ago by Bronze
Sinovac Selected by Beijing CDC to Supply Seasonal Influenza Vaccine Anflu to Beijing Citizens
Oct 13, 8:02AM Benzinga
Oct 13, 8:02AM Benzinga
Sinovac Selected by Beijing CDC to Supply Seasonal Influenza Vaccine Anflu(R) to Beijing Citizens
Oct 13, 8:00AM PR Newswire
Oct 13, 8:00AM PR Newswire
Sinovac Biotech (SVA) Unit Receives Production License for Rabies Vaccine
Sep 27, 8:21AM Street Insider
Sep 27, 8:21AM Street Insider
$SVA http://stks.co/Lhl Bullish engulfing. Could pop through the above 20 and 50MAs. Only like it over $2.42 for a scalp.
about 251 days ago by VexTrades
about 251 days ago by VexTrades
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SVA | 1.85 | +0.03 | +1.65% | 101.08M |
| SUTR | 0.85 | -0.07 | -7.62% | 34.30M |
| SUSS | 28.79 | -0.46 | -1.57% | 612.79M |
| STLY | 3.90 | -0.05 | -1.20% | 56.63M |
| STLD | 10.32 | -0.22 | -2.09% | 2.309B |
| STL | 9.10 | -0.01 | -0.11% | 281.37M |
| STKL | 5.94 | -0.08 | -1.33% | 396.12M |
| STJ | 38.00 | -0.42 | -1.09% | 12.05B |
| STI | 22.25 | -0.67 | -2.92% | 12.36B |
| STFC | 13.47 | -0.18 | -1.32% | 551.19M |
